Bristol Myers Squibb believes Alzheimer's is the largest market for its newly approved schizophrenia drug, Cobenfy, which it expects to eventually generate billions of dollars in revenue.In an interview, company executives said each treatment use they are studying for Cobenfy has multibillion dollar potential, including Alzheimer's disease psychosis, Alzheimer's agitation and Alzheimer's cognition, bipolar disease and autism. But Alzheimer's is the "really large market here," Bristol Myers Squibb CFO David ...